By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know - 2What to know about voluntary chocolate recall
- 3Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- 4Truly amazing Palaces: Which Is Your Number one?
- 5Kate Hudson, 46, says she doesn't need long workouts to feel good
- Weeks-Long Australian LNG Outage Will Further Tighten Supply
- The Beginning Of The End For Fossil Fuels Can Start In Colombia
- Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene
- EU Council president: Ukraine should receive binding guarantees
- 'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- How to avoid or deal with an outrageous medical bill
- 6 US States for Fly Fishing
